BV100 is a new formulation of rifabutin suitable for intravenous administration that BioVersys claims offers a new mechanism ...

President Trump's pick to lead the Department of Health and Human Services (HHS), Robert F Kennedy Jr, will be scrutinised at ...

The ranges were 4.5 to nine years for men and 6.5 to 11 years for women, according to the researchers, who have published ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

The UK government has launched a £150 million ($185 million) procurement drive for artificial intelligence solutions that can ...

It’s always a good sign when a couple of big deals are announced right before the conference, and this year we saw a doozie ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape ...

The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...

At the conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer, who explained a bit more about what a dual-masked T-cell ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Cervical cancer is often highly treatable, with a five-year relative survival rate of 91% for localised, early-stage disease.